A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
OPEN Annals of the rheumatic diseases | 1 Sep 2015
JY Choe, N Prodanovic, J Niebrzydowski, I Staykov, E Dokoupilova, A Baranauskaite, R Yatsyshyn, M Mekic, W Porawska, H Ciferska, K Jedrychowicz-Rosiak, A Zielinska, J Choi, YH Rho and JS Smolen
To compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy.
* Data courtesy of Altmetric.com